Contenuto

Elenco pubblicazioni della Struttura Complessa di Medicina Oncologica 1

  1. Baselga J., Gelmon K.A., Verma S., Wardley A., Conte P.F., Miles D., Bianchi G.V., Cortes J., McNally V.A., Ross G.A., Fumoleau P., Gianni L.:
    Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J
    Clin Oncol 2010; 28: 1138-1144 [IF 17,793]
  2. Capri G., Chang J., Chen S.C., Conte P., Cwiertka K., Jerusalem G., Jiang Z., Johnson S., Kaufman B., Link J., Schutte J., Oliva C., Parikh R., Preston A., Rosenlund J., Selzer M., Zembryki D., De Placido S.:
    An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
    Ann Oncol 2010; 21: 474-480 [IF 5,647]
  3. Demicheli R., Biganzoli E., Ardoino I., Boracchi P., Coradini D., Greco M., Moliterni A., Zambetti M., Valagussa P., Gukas I.D., Bonadonna G.:
    Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: Different mortality but similar recurrence.
    Cancer Sci 2010; 101: 826-830 [IF 3,771]
  4. Early Breast Cancer Trialists' Collaborative Group, (EBCTCG), Bonadonna G., Camerini T., De Palo M., Di Mauro M.G., Formelli F., Valaguassa P.: (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. J Natl Cancer Inst Monogr 2010; 41: 162-177 [IF 14,069]
  5. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., Zambetti M., Vazquez F., Byakhow M., Lichinitser M., Climent M.A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Baronio R., Feyereislova A., Barton C., Valagussa P., Baselga J.:
    Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Lancet 2010; 375: 377-384 [IF 30,758]
  6. Gianni L., Lladò A., Bianchi G.V., Cortes J., Kellokumpu P.L., Cameron D.A., Miles D., Salvagni S., Wardley A., Goeminne J.C., Hersberger V., Baselga J.:
    Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two DoseLevels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
    J Clin Oncol 2010; 28: 1131-1137 [IF 17,793]
  7. Perotti A., Locatelli A., Sessa C., Hess D., Viganò L., Capri G., Maur M., Cerny T., Cresta S., Rojo F., Albanell J., Marsoni S., Corradino I., Berk L., Rivera V.M., Haluska F., Gianni L.:
    Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
    J Clin Oncol 2010; 28: 4554-4561 [IF 17,793]
  8. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G:
    Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer.
    J Clin Oncol 2009 May 20;27(15):2474-2481
  9. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS:
    Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol 2009 Apr 20
  10. Perotti A, Sessa C, Mancuso A, Noberasco C, Cresta S, Locatelli A, Carcangiu ML, Passera K, Braghetti A, Scaramuzza D, Zanaboni F, Fasolo A, Capri G, Miani M, Peters WP, Gianni L :
    Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.
    Ann Oncol. 2009 Apr;20(4):741-745
  11. Mariani G, Fasolo A, De Benedictis E, Gianni L:
    Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer.
    Nat Clin Pract Oncol 2009 Feb;6(2):93-104
  12. Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Viganò L, Maur M, Capri G, Maccioni E, Tosi D, Gianni L:
    Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.
    Eur J Cancer 2008; 44:1829-1834.
  13. Mariani P, Gianni L:.
    The choice of the correct imaging modality in breast cancer management. In: Bombardieri E., Bonadonna G., Gianni L. (Eds.) Breast Cancer. Nuclear Medicine in Diagnosis and Therapeutic Options.
    Springer-Verlag Berlin Heidelberg 2008; 281-292
  14. Mariani G, Gianni L:
    Adjuvant trastuzumab in early breast cancer.
    Ann Oncol 2006; 17 (Suppl. 10):54-58
  15. Mariani G, Petrelli F, Zambetti M, Moliterni A, Fasolo A, Marchianò A, Valagussa P, Gianni L.:
    Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
    Clin Breast Cancer 2006; 7:321-325
  16. Activity of sunitinib in patients with advanced neuroendocrine tumors. Bajetta E, Guadalupi V, Procopio G. J Clin Oncol. 2009 Jan 10;27(2):319-20; author reply 320.
  17. Impact of recent legislative bills regarding clinical research on Italian ethics committee activity. Porcu L, Poli D, Torri V, Rulli E, Di Tullio MC, Cinquini M, Bajetta E, Labianca R, Di Costanzo F, Nitti D, Floriani I. J Med Ethics. 2008 Oct;34(10):747-50.
  18. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Celio L, Denaro A, Canova S, Gevorgyan A, Bajetta E. Tumori. 2008 Jul-Aug;94(4):447-52. Review.
  19. FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer. Cortinovis DL, Andriani F, Livio A, Fabbri A, Perrone F, Marcomini B, Pilotti S, Mariani L, Bidoli P, Bajetta E, Roz L, Sozzi G. Curr Cancer Drug Targets. 2008 Aug;8(5):342-8.
  20. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S. Ann Oncol. 2009 Jan;20(1):84-90. Epub 2008 Jul 31.
  21. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group. J Clin Oncol. 2008 Aug 1;26(22):3695-701.
  22. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Létourneau R, Bajetta E, Pithavala Y, Bycott P, Trask P, Liau K, Ricart AD, Kim S, Rixe O. Lancet. 2008 Jun 21;371(9630):2101-8.
  23. Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Cappelletti V, Gariboldi M, De Cecco L, Toffanin S, Reid JF, Lusa L, Bajetta E, Celio L, Greco M, Fabbri A, Pierotti MA, Daidone MG. Endocr Relat Cancer. 2008 Jun;15(2):439-49.
  24. Oxaliplatin doublets in non-small cell lung cancer: a literature review. Cortinovis D, Bidoli P, Zilembo N, Fusi A, Bajetta E. Lung Cancer. 2008 Jun;60(3):325-31.
  25. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E. Oncology. 2007;73(3-4):204-9.
  26. Pulmonary carcinoid tumours: indolent but not benign. De Dosso S, Bajetta E, Procopio G, Cortinovis D, Buzzoni R, Catena L, Platania M, Verzoni E. Oncology. 2007;73(3-4):162-8. Epub 2008 Apr 16.
  27. Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? Cortinovis D, Bidoli P, Cullurà D, Lorusso V, Ardizzoia A, Amoroso V, Bandera M, Aitini E, Fusi A, Zilembo N, Radula D, Bajetta E. J Thorac Oncol. 2008 Apr;3(4):405-11.
  28. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R. Lancet Oncol. 2008 Feb;9(2):132-8.
  29. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators. Lancet. 2007;370(9605):2103-11.
  30. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Bajetta E. Nat Clin Pract Oncol. 2008 Jan;5(1):4-5.
  31. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG. Br J Cancer. 2007 Dec 3;97(11):1469-74.
  32. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. Di Bartolomeo M, Buzzoni R, Mariani L, Ferrario E, Katia D, Gevorgyan A, Zilembo N, Bordonaro R, Bochicchio AM, Massidda B, Ardizzoia A, Marini G, Aitini E, Schieppati G, Comella G, Pinotti G, Palazzo S, Cicero G, Bajetta E; Italian Trial in Medical Oncology (ITMO) Group, Villa E, Fagnani D, Reguzzoni G, Agostana B, Oliani C, Kildani B, Duro M, Botta M, Mozzana R, Mantovani G. Oncology. 2006;71(5-6):341-6. Erratum in: Oncology. 2007;73(5-6):406.
  33. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Bajetta E, Celio L, Ferrario E, Di Bartolomeo M, Denaro A, Dotti K, Mancin M, Bajetta R, Colombo A, Pusceddu S. Ann Oncol. 2007 Nov;18(11):1810-6.
  34. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M. Ann Oncol. 2008 Jan;19(1):92-8.
  35. Interleukin-12: biological properties and clinical application. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Clin Cancer Res. 2007 Aug 15;13(16):4677-85. Review.
  36. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S. J Clin Oncol. 2007 Aug 1;25(22):3238-45.
  37. National integration of European standards. Bajetta E, Gevorgyan A, Mellstedt H. Ann Oncol. 2007 Jun;18(6):969-70.
  38. Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. Gridelli C, Ferrara C, Guerriero C, Palazzo S, Grasso G, Pavese I, Satta F, Bajetta E, Cortinovis D, Barbieri F, Gebbia V, Grossi F, Novello S, Baldini E, Gasparini G, Latino W, Durante E, Giustini L, Negrini C. J Thorac Oncol. 2007 Jun;2(6):475-80. Erratum in: J Thorac Oncol. 2007 Jul;2(7):676.
  39. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group. J Clin Oncol. 2007 Jun 1;25(16):2212-7.
  40. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study. Lancet. 2007 Feb 17;369(9561):559-70. Erratum in: Lancet. 2007 Mar 17;369(9565):906.
  41. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Bajetta E, Di Bartolomeo M, Buzzoni R, Mariani L, Zilembo N, Ferrario E, Lo Vullo S, Aitini E, Isa L, Barone C, Jacobelli S, Recaldin E, Pinotti G, Iop A. Br J Cancer. 2007 Feb 12;96(3):439-44.
  42. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Bidoli P, Zilembo N, Cortinovis D, Mariani L, Isa L, Aitini E, Cullurà D, Pari F, Nova P, Mancin M, Formisano B, Bajetta E. Ann Oncol. 2007 Mar;18(3):461-7.
  43. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, De Braud F, Loli P, Tartaglia A, Bajetta R, Ferrari L. Cancer. 2006 Nov 15;107(10):2474-81.
  44. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R. Cancer Chemother Pharmacol. 2007 Apr;59(5):637-42.
  45. Capecitabine chemoradiation for rectal cancer after curative surgery. Bajetta E, Beretta E, Di Bartolomeo M, Mariani L, Valvo F, Ferrario E, Mancin M, Dognini G, Buzzoni R. J Chemother. 2006 Feb;18(1):85-9.
  46. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MR, Queirolo P, Taveggia P, Bernengo MG, Legha SS, Formisano B, Cascinelli N. Ann Oncol. 2006 Apr;17(4):571-7.
  47. Pathological features as predictors of recurrence after radical resection of gastric cancer. Buzzoni R, Bajetta E, Di Bartolomeo M, Miceli R, Beretta E, Ferrario E, Mariani L. Br J Surg. 2006 Feb;93(2):205-9.
  48. Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Bajetta E, Catena L, Procopio G, Bichisao E, Ferrari L, Della Torre S, De Dosso S, Iacobelli S, Buzzoni R, Mariani L, Rosai J. Ann Oncol. 2005 Aug;16(8):1374-80.
  49. Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. Helle SI, Mietlowski W, Guastalla JP, Szakolczai I, Bajetta E, Sommer H, Baltali E, Pinter T, Csepreghy M, Ottestad L, Boni C, Bryce C, Klijn JG, Lønning PE. Eur J Cancer. 2005 Mar;41(5):694-701.
  50. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre S, Mariani L, Catena L, Ricotta R, Longarini R, Zilembo N, Buzzoni R. J Clin Oncol. 2005 Apr 1;23(10):2155-61.
Ultimo aggiornamento: giovedì 4 agosto 2011

Menu di approfondimento

accedi al sito www.adobe.com per scaricare la versione freeware di Acrobat Reader

Per visualizzare documenti in formato PDF è necessario Adobe Reader ®.
Scarica la versione gratuita.